A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy
Rainer Landes, Alfredo Illanes, Daniela Goeppner, Harald Gollnick, Michael Friebe, Rainer Landes, Alfredo Illanes, Daniela Goeppner, Harald Gollnick, Michael Friebe
Abstract
Photodynamic Therapy (PDT) using Aminolevulinic acid (ALA) could be an effective and minimally invasively applicable way to treat many different types of tumors without radiation and large incisions by just applying a light pulse. However the PDT process is difficult to observe, control and optimize and the dynamical relationships between the variables involved in the process is complex and still hardly understood. One of the main variables affecting the outcome of the process is the determination of the interval of time between ALA inoculation and starting of light delivery. This interval, better known as drug-light interval, should ensure that enough Protoporphyrin IX (PPIX) is located in the vicinity of functional structures inside the cells for the greatest damage during the PDT procedure. One route to better estimate this time interval would be by predicting PPIX from the dynamical changes of its precursors. For that purpose, in this work a novel optical setup (OS) is proposed for differentiating fluorescence emitted by Coproporphyrin III (CPIII) and PPIX itself in samples composed of mixed solutions. The OS is tested using samples with different concentrations in mixed solutions of PPIX and the precursor CPIII as well as with a Polymethyl methacrylate test sample as additional reference. Results show that emitted fluorescence of the whole process can be measured independently for PPIX and its precursor, which can enable future developments on PPIX prediction from the dynamical changes of its precursor for subject-dependent drug-light interval assessment.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Rapozzi V, Jori G. Basic and Clinical Aspects of Photodynamic Therapy In: Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing; 2014. p. 3–26. Available from: 10.1007/978-3-319-12730-9_1.
- Nakayama T, Otsuka S, Kobayashi T, Okajima H, Matsumoto K, Hagiya Y, et al. Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy. Scientific Reports. 2016;6(1). 10.1038/srep36478
- Dysart JS, Patterson MS. Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro. Physics in Medicine and Biology. 2005;50(11):2597–2616. 10.1088/0031-9155/50/11/011
- Sailer R, Strauss WSL, Wagner M, Emmert H, Schneckenburger H. Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IXin vitro. Comparison between human glioblastoma cells and other cancer cell lines. Photochem Photobiol Sci. 2007;6(2):145–151. 10.1039/b611715e
- Inoue H, Kajimoto Y, Shibata MA, Miyoshi N, Ogawa N, Miyatake SI, et al. Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. Journal of Neuro-Oncology. 2007;83(3):223–231. 10.1007/s11060-006-9325-8
- Morton C, Szeimies RM, Sidoroff A, Wennberg AM, Basset-Seguin N, Calzavara-Pinton P, et al. European Dermatology Forum Guidelines on topical photodynamic therapy. European Journal of Dermatology. 2015;25(4):296–311. 10.1684/ejd.2015.2570
- Ji Z, Yang G, Vasovic V, Cunderlikova B, Suo Z, Nesland JM, et al. Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. Journal of Photochemistry and Photobiology B: Biology. 2006;84(3):213–220. 10.1016/j.jphotobiol.2006.03.006
- Pilný J, Kopečná J, Noda J, Sobotka R. Detection and Quantification of Heme and Chlorophyll Precursors Using a High Performance Liquid Chromatography (HPLC) System Equipped with Two Fluorescence Detectors. BIO-PROTOCOL. 2015;5(3).
- Cohen D, Lee P. Photodynamic Therapy for Non-Melanoma Skin Cancers. Cancers. 2016;8(10):90 10.3390/cancers8100090
- Hillemanns P, Weingandt H, Baumgartner R, Diebold J, Xiang W, Stepp H. Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. Cancer. 2000;88(10):2275–2282. 10.1002/(SICI)1097-0142(20000515)88:10%3C2275::AID-CNCR11%;2-B
- Hindmarsh JT, Oliveras L, Greenway DC. Biochemical differentiation of the porphyrias. Clinical Biochemistry. 1999;32(8):609–619. 10.1016/S0009-9120(99)00067-3
- Huang W, Liu Q, Zhu EY, Shindi AAF, Li YQ. Rapid simultaneous determination of protoporphyrin IX, uroporphyrin III and coproporphyrin III in human whole blood by non-linear variable-angle synchronous fluorescence technique coupled with partial least squares. Talanta. 2010;82(4):1516–1520. 10.1016/j.talanta.2010.07.034
- Swietach P, Vaughan-Jones RD, Harris AL, Hulikova A. The chemistry, physiology and pathology of pH in cancer. Philosophical Transactions of the Royal Society B: Biological Sciences. 2014;369(1638):20130099–20130099. 10.1098/rstb.2013.0099
- Landes R, Illanes A, van Oepen A, Goeppner D, Gollnick H, Friebe M. Fiber-optic filter fluorometer for emission detection of Protoporphyrin IX and its direct precursors—A preliminary study for improved Photodynamic Therapy applications. Results in Physics. 2018;8:1232–1233. 10.1016/j.rinp.2018.01.059
- Dysart JS, Patterson MS. Photobleaching kinetics, photoproduct formation, and dose estimation during ALA induced PpIX PDT of MLL cells under well oxygenated and hypoxic conditions. Photochem Photobiol Sci. 2006;5(1):73–81. 10.1039/b511807g
Source: PubMed